Integrated multi-omics analysis suggests a potential mechanism of DEHP-induced monocyte infiltration in MASH via the

Chaojie Wang1, Zhihao Zhang2, Yuqing Huang3

  • 1School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.

Abstract

Insights

Di-(2-ethylhexyl) phthalate (DEHP) exposure promotes metabolic dysfunction-associated steatohepatitis (MASH) by inhibiting the FOS protein, leading to increased chemokine release and immune cell infiltration. This highlights FOS as a potential biomarker for environment-related liver diseases.

Area of Science:

  • Environmental Health
  • Molecular Biology
  • Hepatology

Background:

  • Di-(2-ethylhexyl) phthalate (DEHP) is an environmental obesogen linked to metabolic dysfunction-associated steatohepatitis (MASH).
  • The precise immune-proinflammatory mechanisms by which DEHP exacerbates MASH are not fully understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms and identify core targets through which DEHP disrupts the hepatic microenvironment and promotes MASH progression.
  • To integrate multi-omics data with experimental validation to characterize the DEHP-driven pathogenic pathways.

Main Methods:

  • Integrated clinical transcriptomic data with machine learning (LASSO, SVM-RFE) to identify key pathogenic genes.
  • Employed single-cell RNA sequencing (scRNA-seq) and virtual knockout (scTenifoldKnk) for cell-type-specific analysis.
  • Validated findings using in vitro assays (siRNA, Western blotting, qPCR, Transwell) and molecular docking.

Main Results:

  • Identified FOS as a core hub gene in DEHP-mediated MASH regulation, demonstrating promising diagnostic potential (AUC=0.964).
  • DEHP exposure suppressed FOS expression in hepatic immune cells, leading to increased CCL3/CCL4 chemokine signaling and monocyte infiltration.
  • In vitro studies confirmed DEHP-induced hepatic lipotoxicity and injury, exacerbated by FOS knockdown, with molecular docking suggesting direct DEHP-FOS interaction.

Conclusions:

  • DEHP promotes MASH by inhibiting FOS, which relieves its suppression of CCL3/CCL4, driving monocyte infiltration and liver injury.
  • FOS emerges as a potential biomarker for environment-related metabolic diseases, warranting further in vivo validation for clinical intervention.